{"protocolSection": {"identificationModule": {"nctId": "NCT00856986", "orgStudyIdInfo": {"id": "NN2211-1842"}, "secondaryIdInfos": [{"id": "2007-005317-19", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes", "officialTitle": "The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes. A 26 Week, Randomised, Open-label, Parallel-group, Multicentre, Multinational Trial With a 26 Week Extension"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2010-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-05", "studyFirstSubmitQcDate": "2009-03-05", "studyFirstPostDateStruct": {"date": "2009-03-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-04-19", "resultsFirstSubmitQcDate": "2011-04-19", "resultsFirstPostDateStruct": {"date": "2011-05-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-25", "lastUpdatePostDateStruct": {"date": "2017-03-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 987, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Lira 1.8", "type": "EXPERIMENTAL", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%", "interventionNames": ["Drug: liraglutide", "Drug: metformin"]}, {"label": "Insulin detemir + Lira 1.8", "type": "EXPERIMENTAL", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%", "interventionNames": ["Drug: liraglutide", "Drug: insulin detemir", "Drug: metformin"]}, {"label": "Non-Randomised Lira 1.8", "type": "EXPERIMENTAL", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%", "interventionNames": ["Drug: liraglutide", "Drug: metformin"]}, {"label": "Early Withdrawals Lira 1.8", "type": "OTHER", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial", "interventionNames": ["Drug: liraglutide", "Drug: metformin"]}, {"label": "Intensified group", "type": "OTHER", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.", "interventionNames": ["Drug: liraglutide", "Drug: insulin detemir", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "liraglutide", "description": "Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.", "armGroupLabels": ["Early Withdrawals Lira 1.8", "Insulin detemir + Lira 1.8", "Intensified group", "Lira 1.8", "Non-Randomised Lira 1.8"]}, {"type": "DRUG", "name": "insulin detemir", "description": "Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm", "armGroupLabels": ["Insulin detemir + Lira 1.8", "Intensified group"]}, {"type": "DRUG", "name": "metformin", "description": "Metformin tablets, at least 1500 mg/day", "armGroupLabels": ["Early Withdrawals Lira 1.8", "Insulin detemir + Lira 1.8", "Intensified group", "Lira 1.8", "Non-Randomised Lira 1.8"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.", "timeFrame": "Week 0 (Randomisation), week 26"}], "secondaryOutcomes": [{"measure": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (for Intensified Subjects in Original Treatment Group)", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (Values Before Intensification as LOCF)", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Fasting Plasma Glucose at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Fasting Plasma Glucose at Week 52", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 26", "description": "Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline/randomisation (week 0) to 26 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 52", "description": "Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline (week 0) to 52 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Fasting Insulin at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Fasting Insulin at Week 52", "timeFrame": "Week 0 (Randomisation), Week 52"}, {"measure": "Mean Change From Randomisation in Fasting Pro-insulin at Week 26.", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Fasting Pro-insulin at Week 52", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Fasting C-peptide at Week 26.", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Fasting C-peptide at Week 52.", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Changes From Randomisation in Cholesterol Lipids at Week 26.", "description": "Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Changes From Randomisation in Cholesterol Lipids at Week 52.", "description": "Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Lipids: Triglycerides at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Lipids: Triglycerides at Week 52", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 52", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Body Weight at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Body Weight at Week 52", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Waist Circumference at Week 26.", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Waist Circumference at Week 52.", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Hip Circumference at Week 26", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Hip Circumference at Week 52", "timeFrame": "Week 0, week 52"}, {"measure": "Mean Change From Randomisation in Waist to Hip Ratio at Week 26", "description": "Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Waist to Hip Ratio at Week 52", "description": "Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference", "timeFrame": "Week 0, Week 52"}, {"measure": "Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 26.", "timeFrame": "Week 0 (Randomisation), Week 26"}, {"measure": "Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 52.", "timeFrame": "Week 0, Week 52"}, {"measure": "Adverse Events From Run-in (Week -12) to Week 52", "timeFrame": "Run-in (week -12) to Week 52"}, {"measure": "Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26", "description": "Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "timeFrame": "weeks 0-26"}, {"measure": "Hypoglycaemic Episodes Weeks 0-52", "description": "Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "timeFrame": "Week 0-52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects diagnosed with type 2 diabetes, insulin na\u00efve and treated with metformin as monotherapy for at least 3 months prior to screening, at a stable dose of at least 1500 mg/day or metformin (at least 1500 mg/day) and a sulfonylurea (less than or equal to half of the maximum approved dose), both at a stable dose for at least 3 months prior to screening. Previous short-term insulin treatment in connection with intercurrent illness is allowed at the discretion of the Investigator\n* HbA1c 7.0-10.0% (both inclusive) for subjects on metformin monotherapy\n* HbA1c 7.0-8.5% (both inclusive) for subjects on metformin in combination with a sulphonylurea\n\nExclusion Criteria:\n\n* Previous treatment with insulin (except for short-term treatment in connection with intercurrent illness at the discretion of the Investigator)\n* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 3 months prior to screening\n* Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the Investigator\n* Impaired kidney function\n* Impaired liver function\n* Uncontrolled treated/untreated hypertension\n* Cancer or any clinically significant disease or disorder as judged by the Investigator\n* Previous participation in the run-in phase of this trial. Re-screening is allowed once\n* History of chronic pancreatitis or idiopathic pancreatitis", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "84 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Alexander City", "state": "Alabama", "zip": "35010", "country": "United States", "geoPoint": {"lat": 32.94401, "lon": -85.95385}}, {"facility": "Novo Nordisk Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novo Nordisk Investigational Site", "city": "Encino", "state": "California", "zip": "91436", "country": "United States", "geoPoint": {"lat": 34.15917, "lon": -118.50119}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Novo Nordisk Investigational Site", "city": "Inglewood", "state": "California", "zip": "90301", "country": "United States", "geoPoint": {"lat": 33.96168, "lon": -118.35313}}, {"facility": "Novo Nordisk Investigational Site", "city": "La Jolla", "state": "California", "zip": "92037", "country": "United States", "geoPoint": {"lat": 32.84727, "lon": -117.2742}}, {"facility": "Novo Nordisk Investigational Site", "city": "Los Gatos", "state": "California", "zip": "95032", "country": "United States", "geoPoint": {"lat": 37.22661, "lon": -121.97468}}, {"facility": "Novo Nordisk Investigational Site", "city": "Montclair", "state": "California", "zip": "91763", "country": "United States", "geoPoint": {"lat": 34.07751, "lon": -117.68978}}, {"facility": "Novo Nordisk Investigational Site", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Novo Nordisk Investigational Site", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Novo Nordisk Investigational Site", "city": "Waterbury", "state": "Connecticut", "zip": "06712", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bradenton", "state": "Florida", "zip": "34201", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "Novo Nordisk Investigational Site", "city": "Clearwater", "state": "Florida", "zip": "33765", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Novo Nordisk Investigational Site", "city": "Jupiter", "state": "Florida", "zip": "33458-7200", "country": "United States", "geoPoint": {"lat": 26.93422, "lon": -80.09421}}, {"facility": "Novo Nordisk Investigational Site", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novo Nordisk Investigational Site", "city": "Miami", "state": "Florida", "zip": "33156", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novo Nordisk Investigational Site", "city": "Miami", "state": "Florida", "zip": "33169", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Novo Nordisk Investigational Site", "city": "Atlanta", "state": "Georgia", "zip": "30308-2253", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Novo Nordisk Investigational Site", "city": "Decatur", "state": "Georgia", "zip": "30033", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Novo Nordisk Investigational Site", "city": "Roswell", "state": "Georgia", "zip": "30076", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "Novo Nordisk Investigational Site", "city": "Savannah", "state": "Georgia", "zip": "31405", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60616", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Novo Nordisk Investigational Site", "city": "Quincy", "state": "Illinois", "zip": "62301", "country": "United States", "geoPoint": {"lat": 39.9356, "lon": -91.40987}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chicago Heights", "state": "Indiana", "zip": "60411", "country": "United States"}, {"facility": "Novo Nordisk Investigational Site", "city": "Louisville", "state": "Kentucky", "zip": "40213", "country": "United States", "geoPoint": {"lat": 38.25424, "lon": -85.75941}}, {"facility": "Novo Nordisk Investigational Site", "city": "Madisonville", "state": "Kentucky", "zip": "42431", "country": "United States", "geoPoint": {"lat": 37.3281, "lon": -87.49889}}, {"facility": "Novo Nordisk Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21204", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hyattsville", "state": "Maryland", "zip": "20782", "country": "United States", "geoPoint": {"lat": 38.95594, "lon": -76.94553}}, {"facility": "Novo Nordisk Investigational Site", "city": "Rockville", "state": "Maryland", "zip": "20852", "country": "United States", "geoPoint": {"lat": 39.084, "lon": -77.15276}}, {"facility": "Novo Nordisk Investigational Site", "city": "Methuen", "state": "Massachusetts", "zip": "01844", "country": "United States", "geoPoint": {"lat": 42.7262, "lon": -71.19089}}, {"facility": "Novo Nordisk Investigational Site", "city": "St. Louis", "state": "Missouri", "zip": "63104", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bronx", "state": "New York", "zip": "10461-2665", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Novo Nordisk Investigational Site", "city": "New Hyde Park", "state": "New York", "zip": "11042", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "Novo Nordisk Investigational Site", "city": "Northport", "state": "New York", "zip": "11768", "country": "United States", "geoPoint": {"lat": 40.90093, "lon": -73.34317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Syracuse", "state": "New York", "zip": "13210", "country": "United States", "geoPoint": {"lat": 43.04812, "lon": -76.14742}}, {"facility": "Novo Nordisk Investigational Site", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Novo Nordisk Investigational Site", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45226", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45245", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dayton", "state": "Ohio", "zip": "45439", "country": "United States", "geoPoint": {"lat": 39.75895, "lon": -84.19161}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novo Nordisk Investigational Site", "city": "Danville", "state": "Pennsylvania", "zip": "17822", "country": "United States", "geoPoint": {"lat": 40.96342, "lon": -76.61273}}, {"facility": "Novo Nordisk Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19152", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novo Nordisk Investigational Site", "city": "State College", "state": "Pennsylvania", "zip": "16801", "country": "United States", "geoPoint": {"lat": 40.79339, "lon": -77.86}}, {"facility": "Novo Nordisk Investigational Site", "city": "Willkes Barre", "state": "Pennsylvania", "zip": "18702", "country": "United States", "geoPoint": {"lat": 41.24591, "lon": -75.88131}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chattanooga", "state": "Tennessee", "zip": "37411", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "Novo Nordisk Investigational Site", "city": "Memphis", "state": "Tennessee", "zip": "38119", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Novo Nordisk Investigational Site", "city": "Corpus Christi", "state": "Texas", "zip": "78412", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75235-6233", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75390-9302", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Midland", "state": "Texas", "zip": "79707", "country": "United States", "geoPoint": {"lat": 31.99735, "lon": -102.07791}}, {"facility": "Novo Nordisk Investigational Site", "city": "Plano", "state": "Texas", "zip": "75075", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novo Nordisk Investigational Site", "city": "Orem", "state": "Utah", "zip": "84058", "country": "United States", "geoPoint": {"lat": 40.2969, "lon": -111.69465}}, {"facility": "Novo Nordisk Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23249", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Novo Nordisk Investigational Site", "city": "Richmond", "state": "Virginia", "zip": "23294", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Novo Nordisk Investigational Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53209", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bonheiden", "zip": "2820", "country": "Belgium", "geoPoint": {"lat": 51.02261, "lon": 4.54714}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "Novo Nordisk Investigational Site", "city": "Edmonton", "state": "Alberta", "zip": "T5J 3N4", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "Novo Nordisk Investigational Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E 3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "Novo Nordisk Investigational Site", "city": "Halifax", "state": "Nova Scotia", "zip": "B3H 2Y9", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "Novo Nordisk Investigational Site", "city": "London", "state": "Ontario", "zip": "N6G 2M1", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mississauga", "state": "Ontario", "zip": "L5M 2V8", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Novo Nordisk Investigational Site", "city": "Smiths Falls", "state": "Ontario", "zip": "K7A 4W8", "country": "Canada", "geoPoint": {"lat": 44.90452, "lon": -76.02333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ajax", "zip": "L1S 7K8", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Novo Nordisk Investigational Site", "city": "Antibes", "zip": "06600", "country": "France", "geoPoint": {"lat": 43.56241, "lon": 7.12777}}, {"facility": "Novo Nordisk Investigational Site", "city": "BRON cedex", "zip": "69677", "country": "France", "geoPoint": {"lat": 45.73333, "lon": 4.91667}}, {"facility": "Novo Nordisk Investigational Site", "city": "CAHORS cedex 9", "zip": "46005", "country": "France", "geoPoint": {"lat": 44.4491, "lon": 1.43663}}, {"facility": "Novo Nordisk Investigational Site", "city": "Corbeil Essonnes", "zip": "91106", "country": "France", "geoPoint": {"lat": 48.60603, "lon": 2.48757}}, {"facility": "Novo Nordisk Investigational Site", "city": "Haguenau", "zip": "67504", "country": "France", "geoPoint": {"lat": 48.81557, "lon": 7.79051}}, {"facility": "Novo Nordisk Investigational Site", "city": "LA ROCHELLE cedex", "zip": "17019", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "Novo Nordisk Investigational Site", "city": "Le Creusot", "zip": "71200", "country": "France", "geoPoint": {"lat": 46.80714, "lon": 4.41632}}, {"facility": "Novo Nordisk Investigational Site", "city": "MARSEILLE cedex 08", "zip": "13285", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Novo Nordisk Investigational Site", "city": "Marseille", "zip": "13008", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Novo Nordisk Investigational Site", "city": "MONTPELLIER cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Montpellier", "zip": "34070", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novo Nordisk Investigational Site", "city": "Narbonne", "zip": "11108", "country": "France", "geoPoint": {"lat": 43.18396, "lon": 3.00141}}, {"facility": "Novo Nordisk Investigational Site", "city": "Paris Cedex 10", "zip": "75475", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novo Nordisk Investigational Site", "city": "Paris", "zip": "75181", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novo Nordisk Investigational Site", "city": "PERPIGNAN cedex", "zip": "66046", "country": "France", "geoPoint": {"lat": 42.69764, "lon": 2.89541}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pessac", "zip": "33600", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"facility": "Novo Nordisk Investigational Site", "city": "Poitiers", "zip": "86000", "country": "France", "geoPoint": {"lat": 46.58333, "lon": 0.33333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Reims", "zip": "51056", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"facility": "Novo Nordisk Investigational Site", "city": "SAINT QUENTIN C\u00e9dex", "zip": "02321", "country": "France", "geoPoint": {"lat": 49.84889, "lon": 3.28757}}, {"facility": "Novo Nordisk Investigational Site", "city": "Saint-denis de La Reunion", "zip": "97405", "country": "France"}, {"facility": "Novo Nordisk Investigational Site", "city": "Saint-pierre de La Reunion", "zip": "97448", "country": "France"}, {"facility": "Novo Nordisk Investigational Site", "city": "Strasbourg", "zip": "67000", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Novo Nordisk Investigational Site", "city": "S\u00e8te", "zip": "34200", "country": "France", "geoPoint": {"lat": 43.4028, "lon": 3.69278}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tours", "zip": "37044", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Augsburg", "zip": "86150", "country": "Germany", "geoPoint": {"lat": 48.37154, "lon": 10.89851}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bad Kreuznach", "zip": "55545", "country": "Germany", "geoPoint": {"lat": 49.8414, "lon": 7.86713}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bad Mergentheim", "zip": "97980", "country": "Germany", "geoPoint": {"lat": 49.4925, "lon": 9.77361}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bad Nauheim", "zip": "61231", "country": "Germany", "geoPoint": {"lat": 50.36463, "lon": 8.73859}}, {"facility": "Novo Nordisk Investigational Site", "city": "Berlin", "zip": "10789", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novo Nordisk Investigational Site", "city": "Berlin", "zip": "12163", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novo Nordisk Investigational Site", "city": "Berlin", "zip": "13055", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bremen", "zip": "28213", "country": "Germany", "geoPoint": {"lat": 53.07516, "lon": 8.80777}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dresden", "zip": "01219", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Novo Nordisk Investigational Site", "city": "Duisburg", "zip": "47051", "country": "Germany", "geoPoint": {"lat": 51.43247, "lon": 6.76516}}, {"facility": "Novo Nordisk Investigational Site", "city": "Eisenach", "zip": "99817", "country": "Germany", "geoPoint": {"lat": 50.9807, "lon": 10.31522}}, {"facility": "Novo Nordisk Investigational Site", "city": "Erfurt", "zip": "99085", "country": "Germany", "geoPoint": {"lat": 50.9787, "lon": 11.03283}}, {"facility": "Novo Nordisk Investigational Site", "city": "Esslingen", "zip": "73728", "country": "Germany", "geoPoint": {"lat": 48.73961, "lon": 9.30473}}, {"facility": "Novo Nordisk Investigational Site", "city": "Frankfurt", "zip": "60388", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novo Nordisk Investigational Site", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Novo Nordisk Investigational Site", "city": "Fulda", "zip": "36037", "country": "Germany", "geoPoint": {"lat": 50.55162, "lon": 9.67518}}, {"facility": "Novo Nordisk Investigational Site", "city": "Gifhorn", "zip": "38518", "country": "Germany", "geoPoint": {"lat": 52.47774, "lon": 10.5511}}, {"facility": "Novo Nordisk Investigational Site", "city": "Grevenbroich", "zip": "41515", "country": "Germany", "geoPoint": {"lat": 51.09102, "lon": 6.5827}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hamburg", "zip": "21073", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hamburg", "zip": "22607", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hohenm\u00f6lsen", "zip": "06679", "country": "Germany", "geoPoint": {"lat": 51.15769, "lon": 12.1}}, {"facility": "Novo Nordisk Investigational Site", "city": "Jena", "zip": "07743", "country": "Germany", "geoPoint": {"lat": 50.92878, "lon": 11.5899}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leipzig", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novo Nordisk Investigational Site", "city": "Limburg", "zip": "65549", "country": "Germany", "geoPoint": {"lat": 48.03138, "lon": 12.18221}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mainz-Ebersheim", "zip": "55129", "country": "Germany", "geoPoint": {"lat": 49.91278, "lon": 8.24083}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novo Nordisk Investigational Site", "city": "Mannheim", "zip": "68163", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Novo Nordisk Investigational Site", "city": "M\u00fcnchen", "zip": "81925", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"facility": "Novo Nordisk Investigational Site", "city": "M\u00fcnster", "zip": "48145", "country": "Germany", "geoPoint": {"lat": 51.96236, "lon": 7.62571}}, {"facility": "Novo Nordisk Investigational Site", "city": "Neuwied", "zip": "56564", "country": "Germany", "geoPoint": {"lat": 50.4336, "lon": 7.47057}}, {"facility": "Novo Nordisk Investigational Site", "city": "Rehlingen-Siersburg", "zip": "66780", "country": "Germany", "geoPoint": {"lat": 49.36023, "lon": 6.66731}}, {"facility": "Novo Nordisk Investigational Site", "city": "Rosenheim", "zip": "83022", "country": "Germany", "geoPoint": {"lat": 47.85637, "lon": 12.12247}}, {"facility": "Novo Nordisk Investigational Site", "city": "Schkeuditz", "zip": "04435", "country": "Germany", "geoPoint": {"lat": 51.39678, "lon": 12.22141}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sinsheim", "zip": "74889", "country": "Germany", "geoPoint": {"lat": 49.2529, "lon": 8.87867}}, {"facility": "Novo Nordisk Investigational Site", "city": "St. Ingbert", "zip": "66386", "country": "Germany"}, {"facility": "Novo Nordisk Investigational Site", "city": "Stuttgart", "zip": "70184", "country": "Germany", "geoPoint": {"lat": 48.78232, "lon": 9.17702}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wangen", "zip": "88239", "country": "Germany", "geoPoint": {"lat": 48.72933, "lon": 9.61175}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ancona", "zip": "60100", "country": "Italy", "geoPoint": {"lat": 43.5942, "lon": 13.50337}}, {"facility": "Novo Nordisk Investigational Site", "city": "Caserta", "zip": "81100", "country": "Italy", "geoPoint": {"lat": 41.07262, "lon": 14.33231}}, {"facility": "Novo Nordisk Investigational Site", "city": "Catanzaro Lido", "country": "Italy", "geoPoint": {"lat": 38.83031, "lon": 16.62781}}, {"facility": "Novo Nordisk Investigational Site", "city": "Catanzaro", "zip": "88100", "country": "Italy", "geoPoint": {"lat": 38.88247, "lon": 16.60086}}, {"facility": "Novo Nordisk Investigational Site", "city": "Chiavari", "zip": "16043", "country": "Italy", "geoPoint": {"lat": 44.31771, "lon": 9.32241}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cosenza", "zip": "87100", "country": "Italy", "geoPoint": {"lat": 39.2989, "lon": 16.25307}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ferrara", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lanciano", "country": "Italy", "geoPoint": {"lat": 42.22718, "lon": 14.39024}}, {"facility": "Novo Nordisk Investigational Site", "city": "Matera (mt)", "zip": "75100", "country": "Italy"}, {"facility": "Novo Nordisk Investigational Site", "city": "Milano", "zip": "20162", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Novo Nordisk Investigational Site", "city": "Milano", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Novo Nordisk Investigational Site", "city": "Monserrato, Cagliari", "zip": "09042", "country": "Italy"}, {"facility": "Novo Nordisk Investigational Site", "city": "Monza", "zip": "20052", "country": "Italy", "geoPoint": {"lat": 45.58005, "lon": 9.27246}}, {"facility": "Novo Nordisk Investigational Site", "city": "Palermo", "zip": "90127", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Novo Nordisk Investigational Site", "city": "Piacenza", "zip": "29100", "country": "Italy", "geoPoint": {"lat": 45.05242, "lon": 9.69342}}, {"facility": "Novo Nordisk Investigational Site", "city": "Primo Piano Palazzina Ambulato", "zip": "40133", "country": "Italy"}, {"facility": "Novo Nordisk Investigational Site", "city": "Ravenna", "zip": "48121", "country": "Italy", "geoPoint": {"lat": 44.41344, "lon": 12.20121}}, {"facility": "Novo Nordisk Investigational Site", "city": "Reggio Calabria", "zip": "89122", "country": "Italy", "geoPoint": {"lat": 38.11047, "lon": 15.66129}}, {"facility": "Novo Nordisk Investigational Site", "city": "Roma", "zip": "00133", "country": "Italy", "geoPoint": {"lat": 41.89193, "lon": 12.51133}}, {"facility": "Novo Nordisk Investigational Site", "city": "Terni", "zip": "05100", "country": "Italy", "geoPoint": {"lat": 42.56335, "lon": 12.64329}}, {"facility": "Novo Nordisk Investigational Site", "city": "Treviglio", "country": "Italy", "geoPoint": {"lat": 45.52081, "lon": 9.59102}}, {"facility": "Novo Nordisk Investigational Site", "city": "Amersfoort", "zip": "3816 CP", "country": "Netherlands", "geoPoint": {"lat": 52.155, "lon": 5.3875}}, {"facility": "Novo Nordisk Investigational Site", "city": "Amsterdam", "zip": "1091 HA", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "Novo Nordisk Investigational Site", "city": "Amsterdam", "zip": "1105 AZ", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "Novo Nordisk Investigational Site", "city": "Beek", "zip": "6191JW", "country": "Netherlands", "geoPoint": {"lat": 50.94083, "lon": 5.79722}}, {"facility": "Novo Nordisk Investigational Site", "city": "Delft", "zip": "2625 AD", "country": "Netherlands", "geoPoint": {"lat": 52.00667, "lon": 4.35556}}, {"facility": "Novo Nordisk Investigational Site", "city": "Doetinchem", "zip": "7001 GW", "country": "Netherlands", "geoPoint": {"lat": 51.965, "lon": 6.28889}}, {"facility": "Novo Nordisk Investigational Site", "city": "Eindhoven", "zip": "5616 GB", "country": "Netherlands", "geoPoint": {"lat": 51.44083, "lon": 5.47778}}, {"facility": "Novo Nordisk Investigational Site", "city": "Groningen", "zip": "9728 NT", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Heerlen", "zip": "6419 PC", "country": "Netherlands", "geoPoint": {"lat": 50.88365, "lon": 5.98154}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hoofddorp", "zip": "2134 TM", "country": "Netherlands", "geoPoint": {"lat": 52.3025, "lon": 4.68889}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hoogeveen", "zip": "7909 AA", "country": "Netherlands", "geoPoint": {"lat": 52.7225, "lon": 6.47639}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leiden", "zip": "2334 CK", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.49306}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leiderdorp", "zip": "2352 RA", "country": "Netherlands", "geoPoint": {"lat": 52.15833, "lon": 4.52917}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lichtenvoorde", "zip": "7131 CM", "country": "Netherlands", "geoPoint": {"lat": 51.98667, "lon": 6.56667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lieshout", "zip": "5737 CB", "country": "Netherlands", "geoPoint": {"lat": 51.52083, "lon": 5.59478}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oude Pekela", "zip": "9665 AR", "country": "Netherlands", "geoPoint": {"lat": 53.10417, "lon": 7.00972}}, {"facility": "Novo Nordisk Investigational Site", "city": "Utrecht", "zip": "3584 CX", "country": "Netherlands", "geoPoint": {"lat": 52.09083, "lon": 5.12222}}, {"facility": "Novo Nordisk Investigational Site", "city": "Voorburg", "zip": "2275 CX", "country": "Netherlands", "geoPoint": {"lat": 52.07417, "lon": 4.35972}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wildervank", "zip": "9648 BE", "country": "Netherlands", "geoPoint": {"lat": 53.08083, "lon": 6.8625}}, {"facility": "Novo Nordisk Investigational Site", "city": "Winschoten", "zip": "9671 CX", "country": "Netherlands", "geoPoint": {"lat": 53.14417, "lon": 7.03472}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bayamon", "zip": "00961", "country": "Puerto Rico", "geoPoint": {"lat": 18.39856, "lon": -66.15572}}, {"facility": "Novo Nordisk Investigational Site", "city": "Carolina", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"facility": "Novo Nordisk Investigational Site", "city": "Trujillo Alto", "zip": "00976", "country": "Puerto Rico", "geoPoint": {"lat": 18.35467, "lon": -66.00739}}, {"facility": "Novo Nordisk Investigational Site", "city": "Almer\u00eda", "zip": "04001", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Novo Nordisk Investigational Site", "city": "Badajoz", "zip": "06080", "country": "Spain", "geoPoint": {"lat": 38.87789, "lon": -6.97061}}, {"facility": "Novo Nordisk Investigational Site", "city": "Badalona", "zip": "08916", "country": "Spain", "geoPoint": {"lat": 41.45004, "lon": 2.24741}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bilbao", "zip": "48013", "country": "Spain", "geoPoint": {"lat": 43.26271, "lon": -2.92528}}, {"facility": "Novo Nordisk Investigational Site", "city": "Cartagena", "zip": "30203", "country": "Spain", "geoPoint": {"lat": 37.60512, "lon": -0.98623}}, {"facility": "Novo Nordisk Investigational Site", "city": "C\u00e1diz", "zip": "11009", "country": "Spain", "geoPoint": {"lat": 36.52672, "lon": -6.2891}}, {"facility": "Novo Nordisk Investigational Site", "city": "C\u00f3rdoba", "zip": "14004", "country": "Spain", "geoPoint": {"lat": 37.89155, "lon": -4.77275}}, {"facility": "Novo Nordisk Investigational Site", "city": "Girona", "zip": "17007", "country": "Spain", "geoPoint": {"lat": 41.98311, "lon": 2.82493}}, {"facility": "Novo Nordisk Investigational Site", "city": "Granada", "zip": "18012", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Madrid", "zip": "28006", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novo Nordisk Investigational Site", "city": "Madrid", "zip": "28031", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novo Nordisk Investigational Site", "city": "Madrid", "zip": "28040", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novo Nordisk Investigational Site", "city": "Majadahonda", "zip": "28222", "country": "Spain", "geoPoint": {"lat": 40.47353, "lon": -3.87182}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pamplona", "zip": "31008", "country": "Spain", "geoPoint": {"lat": 42.81687, "lon": -1.64323}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pontevedra", "zip": "36001", "country": "Spain", "geoPoint": {"lat": 42.431, "lon": -8.64435}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pozuelo de Alarcon", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Novo Nordisk Investigational Site", "city": "Salamanca", "zip": "37007", "country": "Spain", "geoPoint": {"lat": 40.96882, "lon": -5.66388}}, {"facility": "Novo Nordisk Investigational Site", "city": "San Juan", "zip": "03550", "country": "Spain"}, {"facility": "Novo Nordisk Investigational Site", "city": "San Sebasti\u00e1n de los Reyes", "zip": "28700", "country": "Spain", "geoPoint": {"lat": 40.55555, "lon": -3.62733}}, {"facility": "Novo Nordisk Investigational Site", "city": "Santa Cruz de Tenerife", "zip": "38010", "country": "Spain", "geoPoint": {"lat": 28.46824, "lon": -16.25462}}, {"facility": "Novo Nordisk Investigational Site", "city": "Sevilla", "zip": "41013", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tarrasa", "zip": "08221", "country": "Spain"}, {"facility": "Novo Nordisk Investigational Site", "city": "Valencia", "zip": "46010", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Novo Nordisk Investigational Site", "city": "X\u00e1tiva", "zip": "46800", "country": "Spain", "geoPoint": {"lat": 38.99042, "lon": -0.51852}}, {"facility": "Novo Nordisk Investigational Site", "city": "Zaragoza", "zip": "50009", "country": "Spain", "geoPoint": {"lat": 41.65606, "lon": -0.87734}}, {"facility": "Novo Nordisk Investigational Site", "city": "Aberdeen", "zip": "AB25 1LD", "country": "United Kingdom", "geoPoint": {"lat": 57.14369, "lon": -2.09814}}, {"facility": "Novo Nordisk Investigational Site", "city": "Ashton-Under-Lyne", "zip": "OL6 9RW", "country": "United Kingdom", "geoPoint": {"lat": 53.48876, "lon": -2.0989}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bath", "zip": "BA1 3NG", "country": "United Kingdom", "geoPoint": {"lat": 51.3751, "lon": -2.36172}}, {"facility": "Novo Nordisk Investigational Site", "city": "Belfast", "zip": "BT12 6BA", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Novo Nordisk Investigational Site", "city": "Belfast", "zip": "BT16 1RH", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Novo Nordisk Investigational Site", "city": "Belfast", "zip": "BT41 2RL", "country": "United Kingdom", "geoPoint": {"lat": 54.59682, "lon": -5.92541}}, {"facility": "Novo Nordisk Investigational Site", "city": "Blackburn", "zip": "BB2 3HH", "country": "United Kingdom", "geoPoint": {"lat": 53.75, "lon": -2.48333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bristol", "zip": "BS2 8HW", "country": "United Kingdom", "geoPoint": {"lat": 51.45523, "lon": -2.59665}}, {"facility": "Novo Nordisk Investigational Site", "city": "Coventry", "zip": "CV2 2DX", "country": "United Kingdom", "geoPoint": {"lat": 52.40656, "lon": -1.51217}}, {"facility": "Novo Nordisk Investigational Site", "city": "Derby", "zip": "DE22 3NE", "country": "United Kingdom", "geoPoint": {"lat": 52.92277, "lon": -1.47663}}, {"facility": "Novo Nordisk Investigational Site", "city": "Dundee", "zip": "DD1 9SY", "country": "United Kingdom", "geoPoint": {"lat": 56.46913, "lon": -2.97489}}, {"facility": "Novo Nordisk Investigational Site", "city": "Edgbaston, Birmingham", "zip": "B15 2TH", "country": "United Kingdom"}, {"facility": "Novo Nordisk Investigational Site", "city": "Edinburgh", "zip": "EH4 2XU", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Novo Nordisk Investigational Site", "city": "Exeter", "zip": "EX2 5AX", "country": "United Kingdom", "geoPoint": {"lat": 50.7236, "lon": -3.52751}}, {"facility": "Novo Nordisk Investigational Site", "city": "Guildford", "zip": "GU2 7XX", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hull", "zip": "HU3 2JZ", "country": "United Kingdom", "geoPoint": {"lat": 53.7446, "lon": -0.33525}}, {"facility": "Novo Nordisk Investigational Site", "city": "Inverness", "zip": "IV2 3UJ", "country": "United Kingdom", "geoPoint": {"lat": 57.47908, "lon": -4.22398}}, {"facility": "Novo Nordisk Investigational Site", "city": "Leicester", "zip": "LE1 5WW", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Novo Nordisk Investigational Site", "city": "Liverpool", "zip": "L7 8XP", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Novo Nordisk Investigational Site", "city": "Liverpool", "zip": "L9 7AL", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "Novo Nordisk Investigational Site", "city": "Londonderry", "zip": "BT47 6SB", "country": "United Kingdom", "geoPoint": {"lat": 54.9981, "lon": -7.30934}}, {"facility": "Novo Nordisk Investigational Site", "city": "London", "zip": "E1 2EF", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novo Nordisk Investigational Site", "city": "Manchester", "zip": "M41 5SL", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Novo Nordisk Investigational Site", "city": "Manchester", "zip": "M8 5RB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "Novo Nordisk Investigational Site", "city": "Northampton", "zip": "NN1 5BD", "country": "United Kingdom", "geoPoint": {"lat": 52.25, "lon": -0.88333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nuneaton", "zip": "CV10 7DJ", "country": "United Kingdom", "geoPoint": {"lat": 52.52323, "lon": -1.46523}}, {"facility": "Novo Nordisk Investigational Site", "city": "Oxford", "zip": "OX3 7LE", "country": "United Kingdom", "geoPoint": {"lat": 51.75222, "lon": -1.25596}}, {"facility": "Novo Nordisk Investigational Site", "city": "Rugby", "zip": "CV22 5PX", "country": "United Kingdom", "geoPoint": {"lat": 52.37092, "lon": -1.26417}}, {"facility": "Novo Nordisk Investigational Site", "city": "Salford", "zip": "M6 8HD", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "Novo Nordisk Investigational Site", "city": "Swansea", "zip": "SA6 6NL", "country": "United Kingdom", "geoPoint": {"lat": 51.62079, "lon": -3.94323}}, {"facility": "Novo Nordisk Investigational Site", "city": "Welwyn Garden City", "zip": "AL7 4HQ", "country": "United Kingdom", "geoPoint": {"lat": 51.80174, "lon": -0.20691}}]}, "referencesModule": {"references": [{"pmid": "22584132", "type": "RESULT", "citation": "DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14."}, {"pmid": "23746555", "type": "RESULT", "citation": "Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, Seufert J, Thomsen AB, Svendsen CB, DeVries JH; Liraglutide-Detemir Study Group. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications. 2013 Sep-Oct;27(5):492-500. doi: 10.1016/j.jdiacomp.2013.04.008. Epub 2013 Jun 6."}, {"pmid": "25504028", "type": "RESULT", "citation": "Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care. 2015 Jun;38(6):1058-66. doi: 10.2337/dc13-1210. Epub 2014 Dec 12. Erratum In: Diabetes Care. 2015 Aug;38(8):1622."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects on metformin and/or sulpholynurea treatment underwent a 12-week run-in period with liraglutide + metformin. Subjects not achieving an HbA1c below 7% were randomised to liraglutide + metformin treatment with/without insulin detemir. Subjects achieving an HbA1c below 7% continued liraglutide + metformin treatment.", "recruitmentDetails": "A total of 202 centres in 9 countries: Belgium (2), Canada (7), France (19), Germany (37), Italy (18), the Netherlands (16), Spain (14), the United Kingdom (32) and the United States (57)", "groups": [{"id": "FG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "FG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "FG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "FG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "FG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "periods": [{"title": "Run-in Period, Weeks -12-0", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "162"}, {"groupId": "FG002", "numSubjects": "498"}, {"groupId": "FG003", "numSubjects": "167"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "162"}, {"groupId": "FG002", "numSubjects": "498"}, {"groupId": "FG003", "comment": "Subjects who withdrew during run-in and before randomisation were Early Withdrawals", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "167"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "92"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "24"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "10"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "6"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "24"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Main Period, Weeks 0-26", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "161"}, {"groupId": "FG001", "numSubjects": "162"}, {"groupId": "FG002", "numSubjects": "498"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "144"}, {"groupId": "FG002", "numSubjects": "470"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "9"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}, {"title": "Extension Period, Weeks 26-52", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Subjects with HbA1c \u22658.0% who accepted intensification with detemir = 17 (Intensified Group)", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "144"}, {"groupId": "FG002", "comment": "Subjects with HbA1c \u22658.0% who accepted intensification with detemir = 7 (Intensified Group)", "numSubjects": "470"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Enrolled in Extension", "achievements": [{"groupId": "FG000", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "140"}, {"groupId": "FG002", "numSubjects": "461"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "108"}, {"groupId": "FG001", "numSubjects": "130"}, {"groupId": "FG002", "numSubjects": "432"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "38"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Withdrawal Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "BG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "BG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "BG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "BG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "161"}, {"groupId": "BG001", "value": "162"}, {"groupId": "BG002", "value": "498"}, {"groupId": "BG003", "value": "166"}, {"groupId": "BG004", "value": "24"}, {"groupId": "BG005", "value": "1011"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.5", "spread": "9.8"}, {"groupId": "BG001", "value": "57", "spread": "9.5"}, {"groupId": "BG002", "value": "56.7", "spread": "9.7"}, {"groupId": "BG003", "value": "58.7", "spread": "10.8"}, {"groupId": "BG004", "value": "54.3", "spread": "10.3"}, {"groupId": "BG005", "value": "56.9", "spread": "9.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "216"}, {"groupId": "BG003", "value": "75"}, {"groupId": "BG004", "value": "11"}, {"groupId": "BG005", "value": "448"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "89"}, {"groupId": "BG001", "value": "88"}, {"groupId": "BG002", "value": "282"}, {"groupId": "BG003", "value": "91"}, {"groupId": "BG004", "value": "13"}, {"groupId": "BG005", "value": "563"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "48"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "5"}, {"groupId": "BG005", "value": "128"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "450"}, {"groupId": "BG003", "value": "138"}, {"groupId": "BG004", "value": "19"}, {"groupId": "BG005", "value": "883"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "14"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "56"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "141"}, {"groupId": "BG001", "value": "144"}, {"groupId": "BG002", "value": "470"}, {"groupId": "BG003", "value": "146"}, {"groupId": "BG004", "value": "22"}, {"groupId": "BG005", "value": "923"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "1"}, {"groupId": "BG005", "value": "16"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "meter", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.7", "spread": "0.1"}, {"groupId": "BG001", "value": "1.69", "spread": "0.11"}, {"groupId": "BG002", "value": "1.7", "spread": "0.1"}, {"groupId": "BG003", "value": "1.68", "spread": "0.1"}, {"groupId": "BG004", "value": "1.72", "spread": "0.09"}, {"groupId": "BG005", "value": "1.69", "spread": "0.1"}]}]}]}, {"title": "Body weight", "description": "At Week -12", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "98.6", "spread": "21.3"}, {"groupId": "BG001", "value": "99.5", "spread": "21.2"}, {"groupId": "BG002", "value": "99", "spread": "20.8"}, {"groupId": "BG003", "value": "90.2", "spread": "18.5"}, {"groupId": "BG004", "value": "109", "spread": "25.7"}, {"groupId": "BG005", "value": "99", "spread": "21"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "At Week -12", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.9", "spread": "6"}, {"groupId": "BG001", "value": "34.9", "spread": "6.3"}, {"groupId": "BG002", "value": "34.4", "spread": "6.7"}, {"groupId": "BG003", "value": "31.8", "spread": "6"}, {"groupId": "BG004", "value": "36.5", "spread": "7.7"}, {"groupId": "BG005", "value": "34.4", "spread": "6.5"}]}]}]}, {"title": "Diabetes History", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.5", "spread": "6"}, {"groupId": "BG001", "value": "8.6", "spread": "5.8"}, {"groupId": "BG002", "value": "6.6", "spread": "5.7"}, {"groupId": "BG003", "value": "8.4", "spread": "6.4"}, {"groupId": "BG004", "value": "6.8", "spread": "5.4"}, {"groupId": "BG005", "value": "7.4", "spread": "5.8"}]}]}]}, {"title": "Glycosylated haemoglobin (HbA1c)", "description": "At Week -12", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage point of total HbA1c", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "0.8"}, {"groupId": "BG001", "value": "8.2", "spread": "0.7"}, {"groupId": "BG002", "value": "7.7", "spread": "0.7"}, {"groupId": "BG003", "value": "8", "spread": "0.8"}, {"groupId": "BG004", "value": "8.4", "spread": "0.7"}, {"groupId": "BG005", "value": "7.9", "spread": "0.8"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "description": "At Week -12", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.3", "spread": "2.5"}, {"groupId": "BG001", "value": "10.2", "spread": "2.4"}, {"groupId": "BG002", "value": "9.2", "spread": "1.8"}, {"groupId": "BG003", "value": "9.5", "spread": "3"}, {"groupId": "BG004", "value": "10.4", "spread": "2.3"}, {"groupId": "BG005", "value": "9.6", "spread": "2.1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage point of total HbA1c", "timeFrame": "Week 0 (Randomisation), week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.07"}, {"groupId": "OG001", "value": "-0.51", "spread": "0.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The estimated treatment difference between Detemir+Lira 1.8 and Lira 1.8 as well as 95% confidence interval and p-value were calculated by an ANCOVA model with treatment, country and previous OAD as fixed factors and baseline value as covariate. The p-value reflects a two-sided test for the null hypothesis of no difference between the two treatment groups with a significance level of 5% and with the power of 90%.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "ANCOVA", "paramType": "Estimated Treatment Difference, LSMean", "paramValue": "-0.52", "ciPctValue": "95", "ciLowerLimit": "-0.68", "ciUpperLimit": "-0.36"}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (for Intensified Subjects in Original Treatment Group)", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage point of total HbA1c", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.51", "spread": "0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The estimated treatment difference between Detemir+Lira 1.8 and Lira 1.8 as well as 95% confidence interval and p-value were calculated by an ANCOVA model with treatment, country and previous OAD as fixed factors and baseline value as covariate. The p-value reflects a two-sided test for the null hypothesis of no difference between the two treatment groups with a significance level of 5%.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "ANCOVA", "paramType": "Estimated Treatment Difference, LSMean", "paramValue": "-0.41", "ciPctValue": "95", "ciLowerLimit": "-0.6", "ciUpperLimit": "-0.21", "estimateComment": "The analysis values for intensified Lira 1.8 mg subjects were kept in the treatment group and the last observation carried forward (LOCF) method was applied."}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (Values Before Intensification as LOCF)", "populationDescription": "The FAS (Full Analysis Set) includes LOCF of last observation before intensification for randomised Lira 1.8 mg treatment group subjects who were intensified.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Percentage point of total HbA1c", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "149"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.01", "spread": "0.09"}, {"groupId": "OG001", "value": "-0.5", "spread": "0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "ANCOVA", "paramType": "Estimated treatment difference, LS mean", "paramValue": "-0.51", "ciPctValue": "95", "ciLowerLimit": "-0.7", "ciUpperLimit": "-0.31", "estimateComment": "The mean change in HbA1c from randomisation to week 52 was analysed including the values before intensification as LOCF for intensified subjects"}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Plasma Glucose at Week 26", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "0.19"}, {"groupId": "OG001", "value": "-2.12", "spread": "0.19"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Plasma Glucose at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "154"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.14", "spread": "0.21"}, {"groupId": "OG001", "value": "-1.91", "spread": "0.21"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 26", "description": "Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline/randomisation (week 0) to 26 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "144"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Change at Breakfast, N=133, 144", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.97", "spread": "0.26"}, {"groupId": "OG001", "value": "-2.09", "spread": "0.26"}]}]}, {"title": "Change at Lunch, N= 134, 143", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.22"}, {"groupId": "OG001", "value": "-1.43", "spread": "0.22"}]}]}, {"title": "Change at Dinner, N= 133, 139", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "0.24"}, {"groupId": "OG001", "value": "-1.18", "spread": "0.24"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in 7-point Plasma Glucose Profile (Self-measured) at Week 52", "description": "Calculated as an estimate of the change in mean prandial increment of plasma glucose after breakfast, lunch and dinner (from baseline (week 0) to 52 weeks), respectively. Prandial increments of plasma glucose were calculated as the difference between glucose values measured before and after each of these three meals, respectively.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "148"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Change at Breakfast, N=148, 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.68", "spread": "0.25"}, {"groupId": "OG001", "value": "-2.43", "spread": "0.25"}]}]}, {"title": "Change at Lunch, N= 145, 136", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.51", "spread": "0.25"}, {"groupId": "OG001", "value": "-1.14", "spread": "0.25"}]}]}, {"title": "Change at Dinner, N= 144, 135", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.96", "spread": "0.26"}, {"groupId": "OG001", "value": "-1.4", "spread": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Insulin at Week 26", "populationDescription": "Data on fasting insulin could not be obtained for the insulin detemir+liraglutide 1.8 mg+metformin (Detemir + Lira 1.8 group) treated subjects due to cross-reactivity between insulin detemir and the insulin assay. Data from both goups were therefore not further investigated by ANCOVA why no data is presented for this endpoint.", "reportingStatus": "POSTED", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Insulin at Week 52", "populationDescription": "Data on fasting insulin could not be obtained for the insulin detemir+liraglutide 1.8 mg+metformin (Detemir + Lira 1.8 group) treated subjects due to cross-reactivity between insulin detemir and the insulin assay. Data from both goups were therefore not further investigated by ANCOVA why no data is presented for this endpoint.", "reportingStatus": "POSTED", "timeFrame": "Week 0 (Randomisation), Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Pro-insulin at Week 26.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.12", "spread": "3.27"}, {"groupId": "OG001", "value": "-9.78", "spread": "3.22"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting Pro-insulin at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "pmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.47", "spread": "3.08"}, {"groupId": "OG001", "value": "-4", "spread": "3.08"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting C-peptide at Week 26.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "149"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.04"}, {"groupId": "OG001", "value": "-0.32", "spread": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Fasting C-peptide at Week 52.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "139"}, {"groupId": "OG001", "value": "150"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.05"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Mean Changes From Randomisation in Cholesterol Lipids at Week 26.", "description": "Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Change in Total Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "spread": "0.07"}, {"groupId": "OG001", "value": "0.05", "spread": "0.07"}]}]}, {"title": "Change in LDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "0.06"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.06"}]}]}, {"title": "Change in VLDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.05", "spread": "0.03"}, {"groupId": "OG001", "value": "0.01", "spread": "0.03"}]}]}, {"title": "Change in HDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.01"}, {"groupId": "OG001", "value": "0.05", "spread": "0.01"}]}]}]}, {"type": "SECONDARY", "title": "Mean Changes From Randomisation in Cholesterol Lipids at Week 52.", "description": "Cholesterol Lipids cover: Total Cholesterol, Low-density Lipoprotein Cholesterol (LDL-C), Very Low Density Lipoprotein Cholesterol (VLDL-C), High Density Lipoprotein Cholesterol (HDL-C)", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "153"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Change in Total Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.08"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.08"}]}]}, {"title": "Change in LDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.07"}, {"groupId": "OG001", "value": "-0.1", "spread": "0.07"}]}]}, {"title": "Change in VLDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.04"}, {"groupId": "OG001", "value": "-0.03", "spread": "0.04"}]}]}, {"title": "Change in HDL-C", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "0.02"}, {"groupId": "OG001", "value": "0.07", "spread": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Lipids: Triglycerides at Week 26", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "151"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Lipids: Triglycerides at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "141"}, {"groupId": "OG001", "value": "152"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.22", "spread": "0.11"}, {"groupId": "OG001", "value": "-0.37", "spread": "0.11"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 26", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "140"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.02"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Lipids: Free Fatty Acids (FFA) at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "133"}, {"groupId": "OG001", "value": "141"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.03"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Body Weight at Week 26", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.95", "spread": "0.31"}, {"groupId": "OG001", "value": "-0.16", "spread": "0.31"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Body Weight at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (last observation carried forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.02", "spread": "0.41"}, {"groupId": "OG001", "value": "-0.05", "spread": "0.42"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Waist Circumference at Week 26.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.46"}, {"groupId": "OG001", "value": "-0.78", "spread": "0.46"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Waist Circumference at Week 52.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "participants", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.54"}, {"groupId": "OG001", "value": "-0.83", "spread": "0.53"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Hip Circumference at Week 26", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.36", "spread": "0.46"}, {"groupId": "OG001", "value": "-0.38", "spread": "0.45"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Hip Circumference at Week 52", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm", "timeFrame": "Week 0, week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.79", "spread": "0.5"}, {"groupId": "OG001", "value": "-0.28", "spread": "0.49"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Waist to Hip Ratio at Week 26", "description": "Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm/cm", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00356", "spread": "0.004071"}, {"groupId": "OG001", "value": "-0.00332", "spread": "0.004032"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Waist to Hip Ratio at Week 52", "description": "Waist to Hip Ratio is calculated by dividing Waist circumference with Hip circumference", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "cm/cm", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "160"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.00146", "spread": "0.004165"}, {"groupId": "OG001", "value": "-0.00438", "spread": "0.004126"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 26.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Week 0 (Randomisation), Week 26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Systolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.11", "spread": "1.22"}, {"groupId": "OG001", "value": "0.41", "spread": "1.23"}]}]}, {"title": "Diastolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.4", "spread": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Randomisation in Blood Pressure (Systolic and Diastolic) at Week 52.", "populationDescription": "The FAS (Full Analysis Set) using LOCF (Last Observation Carried Forward) is all randomised subjects with at least one of any efficacy value after the randomisation visit (baseline)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "157"}, {"groupId": "OG001", "value": "162"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Systolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.74", "spread": "1.2"}, {"groupId": "OG001", "value": "0.16", "spread": "1.21"}]}]}, {"title": "Diastolic Blood Pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.66", "spread": "0.78"}, {"groupId": "OG001", "value": "0.11", "spread": "0.79"}]}]}]}, {"type": "SECONDARY", "title": "Adverse Events From Run-in (Week -12) to Week 52", "populationDescription": "The Safety Analysis Set included all exposed subjects", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "Run-in (week -12) to Week 52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "499"}, {"groupId": "OG003", "value": "166"}, {"groupId": "OG004", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "716"}, {"groupId": "OG001", "value": "845"}, {"groupId": "OG002", "value": "2389"}, {"groupId": "OG003", "value": "383"}, {"groupId": "OG004", "value": "30"}]}]}]}, {"type": "SECONDARY", "title": "Hypoglycaemic Episodes (Excluding Outlier Subject), Weeks 0-26", "description": "Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "populationDescription": "The Safety Analysis Set included all exposed subjects. An outlier subject from the lira 1.8 group, who experienced an extreme number of minor and symptoms only hypoglycaemic episodes was excluded from this analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "weeks 0-26", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "499"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "31"}]}]}, {"title": "Symptoms only", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "26"}]}]}]}, {"type": "SECONDARY", "title": "Hypoglycaemic Episodes Weeks 0-52", "description": "Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L.", "populationDescription": "The Safety Analysis Set included all exposed subjects. An outlier subject from the lira 1.8 group, who experienced an extreme number of minor and symptoms only hypoglycaemic episodes was excluded from this analysis", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "episodes", "timeFrame": "Week 0-52", "groups": [{"id": "OG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%"}, {"id": "OG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%"}, {"id": "OG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial"}, {"id": "OG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "163"}, {"groupId": "OG002", "value": "499"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "24"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG004", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "33"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG004", "value": "1"}]}]}, {"title": "Symptoms only", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "57"}, {"groupId": "OG002", "value": "42"}, {"groupId": "OG004", "value": "2"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG004", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a timeframe of 64 weeks (from run-in to week 52).", "description": "The Safety Analysis Set included all exposed subjects", "eventGroups": [{"id": "EG000", "title": "Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%", "seriousNumAffected": 11, "seriousNumAtRisk": 159, "otherNumAffected": 100, "otherNumAtRisk": 159}, {"id": "EG001", "title": "Insulin Detemir + Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%", "seriousNumAffected": 17, "seriousNumAtRisk": 163, "otherNumAffected": 102, "otherNumAtRisk": 163}, {"id": "EG002", "title": "Non-Randomised Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%", "seriousNumAffected": 62, "seriousNumAtRisk": 499, "otherNumAffected": 310, "otherNumAtRisk": 499}, {"id": "EG003", "title": "Early Withdrawals Lira 1.8", "description": "Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial", "seriousNumAffected": 6, "seriousNumAtRisk": 166, "otherNumAffected": 122, "otherNumAtRisk": 166}, {"id": "EG004", "title": "Intensified Group", "description": "Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c \u2265 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.", "seriousNumAffected": 1, "seriousNumAtRisk": 24, "otherNumAffected": 11, "otherNumAtRisk": 24}], "seriousEvents": [{"term": "Ankle Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Head Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Joint Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Femur Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Ligament Rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Traumatic Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Traumatic Intracranial Haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Abdominal Hernia Obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Intestinal Infarction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Pancreatitis Chronic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Sarcoidosis", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Clostridium Difficile Colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Helicobacter Gastritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Post Procedural Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Viral Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Interverterbal Disc Degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Interverterbal Disc Protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Polymyalgia Rheumatica", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Benign Intracranial Hypertension", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Cerebrovascular Accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Transient Ischaemic Attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Urinary Retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Bronchopulmonary Disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Nasal Septum Deviation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Peripheral Arterial Occlusive Disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Coronary Artery Disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Supraventricular Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 5, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Macular Ischaemia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Macular Oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Breast Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Metastases to Central Nervous System", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Renal Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Thyroid Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Uterine Leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Tendon Rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Post Lumbar Puncture Syndrome", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Rib Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Upper Limb Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Food Poisoning", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Injection site abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Muscle abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Carotid Artery Stenosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Partial Seizures", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Renal Colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Renal Failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Cystocele", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Breast hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Erectile Dysfunction", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Fibrocystic Breast Disease", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Vaginal Haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Lung Squamous Cell Carcinoma Unspecified", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "B-Cell Lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Fibroadenoma of Breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 0}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Gallbladder Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Gastric Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Metastases to liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Prostate Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Pulmonary Mass", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Poor Peripheral Circulation", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Febrile neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Thrombocytopenic purpura", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Vertigo Positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Thyroid ccell hyperplasia", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "ECG abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "ECG change", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Medical device removal", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 57, "numAffected": 40, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 45, "numAffected": 33, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 97, "numAffected": 72, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 24}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 29, "numAffected": 26, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 42, "numAffected": 29, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 108, "numAffected": 74, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 25, "numAffected": 21, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 51, "numAffected": 37, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 40, "numAffected": 30, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 204, "numAffected": 136, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 72, "numAffected": 66, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Lipase Increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 27, "numAffected": 26, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 60, "numAffected": 55, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 7, "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 4, "numAffected": 4, "numAtRisk": 24}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 23, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 54, "numAffected": 21, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 144, "numAffected": 73, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 22, "numAffected": 13, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 2, "numAffected": 2, "numAtRisk": 24}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 19, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 26, "numAffected": 17, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 113, "numAffected": 50, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 25, "numAffected": 21, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 8, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 54, "numAffected": 42, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 42, "numAffected": 33, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 30, "numAffected": 25, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 11, "numAffected": 11, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 8, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 17, "numAffected": 14, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 6, "numAffected": 5, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 9, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 24, "numAffected": 21, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 16, "numAffected": 15, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 8, "numAffected": 6, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Back Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 30, "numAffected": 26, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 5, "numAffected": 4, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 24}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 10, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 19, "numAffected": 17, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}, {"term": "Decreased Appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 159}, {"groupId": "EG001", "numEvents": 13, "numAffected": 13, "numAtRisk": 163}, {"groupId": "EG002", "numEvents": 53, "numAffected": 50, "numAtRisk": 499}, {"groupId": "EG003", "numEvents": 17, "numAffected": 17, "numAtRisk": 166}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 24}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk reserves the right not to release data until specified milestones, e.g. a clinical trial report is available. This includes the right not to release interim results from clinical trials.\n\nAt the end of the trial, one or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications. Novo Nordisk reserves the right to postpone publication for a short time to protect intellectual property."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069450", "term": "Liraglutide"}, {"id": "D000069057", "term": "Insulin Detemir"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M419", "name": "Liraglutide", "asFound": "Cessation", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M349", "name": "Insulin Detemir", "asFound": "Oocyte", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}